Summary & Overview
HCPCS J9227: Injection, Isatuximab-irfc, 10 mg
HCPCS Level II code J9227 denotes an injection of isatuximab-irfc, billed per 10 mg, representing administration of a targeted monoclonal antibody used in oncology care. Nationally, accurate coding of biologic infusions like isatuximab is important for proper claim adjudication, clinical documentation, and tracking of high-cost specialty drugs across inpatient and outpatient settings. This code is relevant for infusion centers, outpatient hospital clinics, and physician offices where therapeutic injections are provided.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for isatuximab administration, common sites of service, and the range of payer coverage considerations. The publication summarizes benchmarks and utilization insights where available, highlights policy and reimbursement updates affecting biologic infusion billing, and outlines operational considerations for coding and claim submission.
The content provides practical reference material—code definition, service type, typical site of service, and payer landscape—so billing staff, revenue cycle managers, and policy analysts can reference the code in a national context. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9227 represents an injection of isatuximab-irfc, billed per 10 mg unit. This code is used for administration of the monoclonal antibody isatuximab, an oncology biologic therapy.
Service Type: Therapeutic infusion/injection
Typical Site of Service: Infusion center, outpatient hospital clinic, or physician office
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma receiving intravenous immunotherapy with J9227 (isatuximab-irfc) dosed per weight and regimen. The clinical workflow begins with an oncology clinic visit where the hematologist/oncologist documents disease status, prior therapies, and confirms eligibility for isatuximab. Pre‑infusion orders include baseline labs (CBC, CMP), infection screening, and premedications (antihistamine, corticosteroid, antipyretic). On infusion day the patient checks in to the infusion center or hospital outpatient infusion unit; vital signs and weight are confirmed, premedications are administered, and the infusion nurse prepares and administers J9227 per institutional protocol using an appropriate IV line. During infusion the nurse monitors for infusion‑related reactions and documents start/stop times, lot number, and vial count. After completion, the patient is observed for a mandated period for adverse reactions and discharged with follow‑up oncology clinic scheduling. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or physician office infusion suites depending on payer and facility capabilities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default when no modifier applies |